UCB traded at 82.60 this Tuesday July 5th, decreasing 0.04 or 0.05 percent since the previous trading session. Looking back, over the last four weeks, UCB lost 1.65 percent. Over the last 12 months, its price fell by 6.92 percent. Looking ahead, we forecast UCB to be priced at 80.24 by the end of this quarter and at 73.55 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
82.60
Daily Change
-0.05%
Yearly
-6.92%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Alcon AG 67.84 -0.12 -0.18% 3.92%
Almirall SA 10.87 0.08 0.74% -28.01%
Amarin 1.59 0.15 10.42% -62.50%
argenx SE 368.10 6.80 1.88% 39.43%
Artemis Alpha 298.00 1.46 0.49% -33.18%
AstraZeneca 10,800.00 -8.00 -0.07% 23.84%
Bayer 55.52 -1.72 -3.00% 9.55%
Genmab 2,407.00 54.00 2.29% -8.41%
Galapagos 54.90 1.84 3.47% -5.08%
GRIFOLS 17.56 -0.28 -1.54% -21.61%
GlaxoSmithKline 1,786.60 -16.00 -0.89% 24.57%
Hikma Pharmaceutical 1,638.00 -16.00 -0.97% -35.94%
Lonza Group 529.60 4.80 0.91% -20.46%
Merck 167.85 2.45 1.48% 1.39%
Novartis 80.91 -0.74 -0.91% -4.31%
Orion 43.72 0.97 2.27% 17.97%
Recordati 42.91 -0.11 -0.26% -14.35%
Roche Holding 319.00 -3.60 -1.12% -9.76%
Sanofi 97.12 -1.22 -1.24% 11.93%
UCB 82.60 -0.04 -0.05% -6.92%
Unibail Rodamco 46.14 -1.35 -2.83% -38.54%

Indexes Price Day Year
BE20 3663 -30.89 -0.84% -11.93%
EU100 1124 -30.03 -2.60% -11.10%

UCB
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.